| Not Yet Recruiting | Plant-Based Nutrition for Breast or Endometrial Cancer NCT07189702 | University of Rochester | N/A |
| Not Yet Recruiting | Screening for Brain Metastases NCT07492121 | University of Zurich | Phase 2 |
| Not Yet Recruiting | Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice NCT06882499 | Peter MacCallum Cancer Centre, Australia | N/A |
| Not Yet Recruiting | Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin- NCT06849947 | Yeon Hee Park | Phase 2 |
| Recruiting | Nutrition Awareness Among Women With Non-Metastatic Breast Cancer NCT07389967 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505 | SAPU NANO (US) LLC | Phase 1 |
| Recruiting | ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positiv NCT07007559 | ALX Oncology Inc. | Phase 2 |
| Recruiting | A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic NCT07292168 | Kidney Cancer Research Bureau | Phase 1 / Phase 2 |
| Not Yet Recruiting | First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. NCT07299409 | Nathalie Levasseur | Phase 2 |
| Recruiting | Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progress NCT07137871 | The University of Texas Health Science Center at San Antonio | Phase 1 |
| Withdrawn | A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer NCT07076680 | SciClone Pharmaceuticals | — |
| Not Yet Recruiting | Artificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer NCT07063667 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Enrolling By Invitation | Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DX NCT06680596 | UNICANCER | Phase 2 |
| Recruiting | Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Can NCT06616987 | Yeon Hee Park | Phase 2 |
| Recruiting | Trial of Trastuzumab Deruxtecan in Previously Treated HER2 NCT06750484 | Yale University | Phase 2 |
| Recruiting | A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients NCT06746688 | ExpreS2ion Biotechnologies | Phase 1 |
| Not Yet Recruiting | A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Met NCT06975462 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Enrolling By Invitation | Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment NCT06914661 | The First Hospital of Jilin University | — |
| Recruiting | SLV-154 Treatment of Metastatic Solid Tumors NCT06771219 | Solve Therapeutics | Phase 1 |
| Active Not Recruiting | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer NCT06878248 | Calibr, a division of Scripps Research | Phase 1 |
| Active Not Recruiting | Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer NCT06876636 | Xijing Hospital | N/A |
| Recruiting | Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device NCT06807502 | ScreenCell | N/A |
| Recruiting | To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast NCT06784921 | Zhejiang Cancer Hospital | — |
| Recruiting | Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in NCT07154563 | Yunnan Cancer Hospital | — |
| Recruiting | Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis NCT06718933 | Fudan University | Phase 1 / Phase 2 |
| Recruiting | Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast NCT06611891 | University Hospital, Grenoble | Phase 3 |
| Recruiting | Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/H NCT06762483 | European Institute of Oncology | — |
| Recruiting | HER2-PET Imaging in HER2-low Breast Cancers NCT06732336 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Phase 1 / Phase 2 |
| Recruiting | 21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis NCT06891651 | Qilu Hospital of Shandong University | — |
| Not Yet Recruiting | Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Ma NCT06728150 | Monash University | — |
| Active Not Recruiting | A ReaL World Study of DS-8201 NCT06945224 | Fudan University | — |
| Recruiting | A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer NCT06658080 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | PIK3CA Mutational Status Assessment NCT06706570 | European Institute of Oncology | — |
| Recruiting | Target-specific immunoPET Imaging of Breast Cancer NCT06715826 | RenJi Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer NCT06612814 | Zhimin Shao | Phase 3 |
| Recruiting | TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer NCT06532812 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | A Real World Study of Sacituzumab Govitecan NCT06966141 | Fudan University | — |
| Recruiting | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer NCT06439693 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable NCT06663787 | Nagoya City University | — |
| Recruiting | Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast NCT06800612 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monothe NCT06298084 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 / Phase 2 |
| Recruiting | RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer NCT07003009 | Istanbul Training and Research Hospital | N/A |
| Recruiting | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. NCT06072612 | BriaCell Therapeutics Corporation | Phase 3 |
| Active Not Recruiting | A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After NCT06100874 | Adrienne G. Waks | Phase 2 |
| Enrolling By Invitation | Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Rec NCT06857305 | Ma Fei，MD | Phase 3 |
| Completed | Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients NCT05837533 | Medicos e Investigadores en la Lucha contra el Cancer de Mama | N/A |
| Recruiting | Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan NCT06805812 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced C NCT05735080 | Incyclix Bio | Phase 1 / Phase 2 |
| Recruiting | Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer NCT05759572 | Fudan University | Phase 2 |
| Recruiting | PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer NCT05759546 | Fudan University | Phase 2 |
| Recruiting | Integrin αvβ6-targeted PET in Malignant Tumors NCT05835570 | Zhongnan Hospital | — |
| Recruiting | A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA NCT05420779 | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross NCT05463276 | Sindh Institute of Urology and Transplantation | — |
| Terminated | Sitravatinib in Metastatic Breast Cancer NCT04123704 | Xiang Zhang | Phase 2 |
| Completed | ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL NCT04603183 | MedSIR | Phase 2 |
| Recruiting | Radiotherapy for Extracranial Oligometastatic Breast Cancer NCT04646564 | Chinese Academy of Medical Sciences | Phase 3 |
| Terminated | Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors NCT04659603 | Sanofi | Phase 2 |
| Unknown | Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer NCT05033769 | Institut fuer Frauengesundheit | Phase 4 |
| Recruiting | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042 | General Oncology, Inc. | Phase 1 |
| Completed | Real World Study of Bone Metastases in Patients with Advanced Breast Cancer NCT06873997 | Zhejiang Cancer Hospital | — |
| Completed | Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. NCT04483505 | Fundacion CRIS de Investigación para Vencer el Cáncer | Phase 1 |
| Completed | DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metas NCT04509596 | Dizal Pharmaceuticals | Phase 1 |
| Unknown | A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients NCT04556292 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 2 |
| Completed | Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LU NCT04240106 | MedSIR | Phase 2 |
| Active Not Recruiting | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With NCT04215146 | Oncolytics Biotech | Phase 2 |
| Unknown | A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Pati NCT04262804 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 |
| Unknown | Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases NCT04167605 | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | — |
| Terminated | A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer NCT04197999 | GlycoMimetics Incorporated | Phase 1 |
| Terminated | NR in Chemo-induced Peripheral Neuropathy NCT03642990 | Donna Hammond, PhD | Phase 2 |
| Completed | Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer NCT05609903 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Terminated | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-posit NCT04059484 | Sanofi | Phase 2 |
| Unknown | Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation NCT04368442 | Samsung Medical Center | — |
| Recruiting | The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease NCT04122469 | University Health Network, Toronto | N/A |
| Active Not Recruiting | Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer NCT03742245 | The Methodist Hospital Research Institute | Phase 1 |
| Completed | Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metas NCT05301530 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Phase 1 |
| Completed | Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Comb NCT05155566 | Pfizer | — |
| Active Not Recruiting | Personalised Disease Monitoring in Metastatic Breast Cancer NCT04597580 | The Christie NHS Foundation Trust | — |
| Completed | Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer NCT04350021 | Vastra Gotaland Region | — |
| Active Not Recruiting | Screening For BCRL In Targeted Therapy For Breast Cancer NCT05142800 | Massachusetts General Hospital | — |
| Unknown | Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer NCT03638765 | Northwest Biotherapeutics | Phase 1 |
| Terminated | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Meta NCT03709082 | University of Kansas Medical Center | Phase 1 / Phase 2 |
| Completed | Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System NCT03427450 | Angle plc | — |
| Completed | Combination Study of SV-BR-1-GM With Retifanlimab NCT03328026 | BriaCell Therapeutics Corporation | Phase 1 / Phase 2 |
| Completed | Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer NCT03555877 | GBG Forschungs GmbH | Phase 2 |
| Completed | Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cance NCT05301010 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Phase 3 |
| Completed | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. NCT03321981 | Merus B.V. | Phase 2 |
| Terminated | HR+/HER2- Advanced Breast Cancer and Endocrine Resistance NCT03322215 | Theodoros Foukakis | Phase 2 |
| Completed | Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer NCT03045653 | Sun Yat-sen University | Phase 2 |
| Completed | E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research NCT03132506 | University Hospital Tuebingen | — |
| Completed | Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients NCT03328884 | MedSIR | Phase 2 |
| Unknown | Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Pat NCT03086785 | Hebei Medical University Fourth Hospital | Phase 2 |
| Completed | Investigation of Cancer Cell Extravasation Through mRNA Analysis of Organ-specific Endothelial Cells and Micro NCT04047459 | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | — |
| Completed | GISEL:Registry of Breast Cancer Patients Treated With ECT NCT06683404 | Istituto Oncologico Veneto IRCCS | — |
| Completed | Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Canc NCT02664103 | Sanofi | Phase 2 |
| Unknown | Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer NCT03002532 | Affiliated Hospital to Academy of Military Medical Sciences | N/A |
| Completed | Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cance NCT02511639 | Istituto Oncologico Veneto IRCCS | Phase 3 |
| Completed | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Tre NCT02000622 | AstraZeneca | Phase 3 |
| Terminated | A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer NCT01876251 | Pfizer | Phase 1 |
| Terminated | Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer NCT01067989 | HaEmek Medical Center, Israel | Phase 2 |
| Completed | Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple N NCT01045304 | Sanofi | Phase 2 |
| Completed | Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC NCT00532714 | National Cancer Center, Korea | Phase 2 |
| Completed | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer NCT00288249 | Bayer | Phase 2 |
| Completed | Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients NCT00044525 | Bayer | Phase 2 |
| Completed | Study for Using Radiosurgery on Limited Metastases of Breast Cancer NCT00167414 | University of Rochester | N/A |